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Abstract: Australia’s response to the human immunodeficiency virus type 1 (HIV-1) pandemic led
to effective control of HIV transmission and one of the world’s lowest HIV incidence rates—0.14%.
Although there has been a recent decline in new HIV diagnoses in New South Wales (NSW), the most
populous state in Australia, there has been a concomitant increase with non-B subtype infections,
particularly for the HIV-1 circulating recombinant form CRF01_AE. This aforementioned CRF01_AE
sampled in NSW, were combined with those sampled globally to identify NSW-specific viral clades.
The population growth of these clades was assessed in two-year period intervals from 2009 to 2017.
Overall, 109 NSW-specific clades were identified, most comprising pairs of sequences; however, five
large clades comprising ≥10 sequences were also found. Forty-four clades grew over time with one
or two sequences added to each in different two-year periods. Importantly, while 10 of these clades
have seemingly discontinued, the remaining 34 were still active in 2016/2017. Seven such clades
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each comprised ≥10 sequences, and are representative of individual sub-epidemics in NSW. Thus,
although the majority of new CRF01_AE infections were associated with small clades that rarely
establish ongoing chains of local transmission, individual sub-epidemics are present and should be
closely monitored.
Keywords: HIV-1 CRF01_AE; transmission cluster; evolution; cluster growth; sub-epidemic
1. Introduction
The human immunodeficiency virus type 1 (HIV-1) is still a major burden worldwide with
approximately 36.9 million individuals infected with HIV globally (WHO). The Joint United Nations
Programme on HIV/AIDS (UNAIDS) set the 90/90/90 targets with the aim that by 2020 90% of all
people living with HIV-1 know their status, 90% of these will be receiving antiretroviral therapy, and
90% of these will have an undetectable plasma viral load [1]. The latter is of particular importance, as
infected people that are virally suppressed do not develop the acquired immunodeficiency syndrome
(AIDS) [2], and cannot transmit the virus further while on treatment [3]. Australia has an estimated
HIV-1 prevalence of 0.14%, with approximately 1000 new infections annually [4]. New South Wales
(NSW) is the most populous state in Australia, and has the highest HIV-1 burden, with approximately
10,100 people living with HIV-1 [5]. Importantly, NSW achieved the 90/90/90 targets in 2016 [5,6], and
has experienced the first decline in new infections in ten years [7]. However, this decline was only
observed in Australian-born men-who-have-sex-with-men (MSM), and an increase in new infections
was observed in overseas-born MSM [6], indicating that there are differences in how different risk
groups have been impacted by public health interventions.
HIV-1 circulates globally as different genetically defined subtypes, although the subtype prevalence
varies across different countries; subtype C is most prevalent in Africa (and globally), the circulating
recombinant form 01_AE (CRF01_AE) is most prevalent in Southeast Asia, and subtype B is most
prevalent in the USA, Europe, and Australia [8]. This is of current importance because the HIV-1
epidemic in Australia is experiencing a shift in subtype incidence with a major increase in non-B
infections, as an estimated 20% of all new infections in Australia were of non-B origin in 2006, and that
increased to 38% in 2016 [9]. CRF01_AE is of particular interest for Australia due to the close proximity
to Southeast Asia, with both travel and migration between these regions representing a conduit
for HIV-1 importation [10]. Yet, little is known about the geographic origins and epidemiological
characteristics of CRF01_AE in Australia.
To better understand the phylodynamics of CRF01_AE in NSW we (i) identified independent
transmission clades, (ii) estimated clade growth over time, and (iii) assessed the impact of transmission
clade growth on the NSW epidemic.
2. Materials and Methods
2.1. Ethics
This study was approved by the NSW Population and Health Services Research Ethics Committee
and the ACON Research Ethics Review Committee (RERC) [AU RED Reference: HREC/15/CIHS/38,
Cancer Institute NSW reference number: 2015/08/605]. The HIV/AIDS Legal Centre was consulted for
legal advice on data anonymity.
2.2. HIV-1 Sequence Data
Protease and reverse transcriptase sequences sampled between 2004 and 2017 were obtained
from the three laboratories performing HIV genotypic drug resistance testing for HIV-1 in NSW; St.
Vincent’s HIV State Reference Laboratory, New South Wales Health Pathology-Royal Prince Alfred
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Hospital, and New South Wales Health Pathology Institute of Clinical Pathology and Medical Research
(ICPMR).
The final data set was created by the Center for Health Record Linkage (CHeReL) by linking the
individual sequence identifiers obtained from the laboratories performing resistance testing to HIV
notification case identifiers from the NSW HIV registry. Patient data always remained anonymized.
The earliest available sequence for each patient was used for the analyses to avoid including multiple
sequences from the same patient (n = 7000). HIV-1 subtype was determined using the REGA HIV-1
Subtyping Tool Version 3.0 [11].
2.3. Phylogenetic Analysis
A maximum likelihood tree including 83 HIV-1 reference sequences from the REGA tool and the
7000 NSW sequences was estimated using FastTreeMP v2.1.10 [12] via the CIPRES Science Gateway [13],
implementing a GTR+Γ model of nucleotide substitution, and accounting for invariable sites, and
NNI branch-swapping was implemented for topology search. Sequences forming a monophyletic
CRF01_AE group (n = 758) were used for subsequent analyses. All HIV-1 sequences were retrieved
from the Los Alamos HIV database (http://www.hiv.lanl.gov/) and used for comparison. NSW protease
and reverse transcriptase nucleotide sequences were blasted against the global database, and the
best 50 hits for each NSW sequence were retrieved from the global database [14]. Accordingly,
a total of 2807 global sequences were used as background sequence data; three HIV-1 subtype
G sequences (accession numbers DQ168576 and EU786670) were added as an outgroup to root
the phylogeny (Table S1). Pairwise alignment was performed in Mafft, implementing the L-INS-I
algorithm [15]. The sequences from the Los Alamos HIV database, as well as the sequences obtained
from the three reference laboratories in NSW differ slightly in their length and genome position.
As a consequence, the alignment was reduced to the nucleotide positions 2253–3384, based on the
reference sequence HXB2 (accession number K03455.1). The alignment was visually inspected in
Geneious 11.1.3 (https://www.geneious.com), and sequences that were too short were removed as
well as codons associated with drug resistance mutations (according to reference sequence HXB2;
accession number K03455.1) [16]. The final alignment comprised 3510 sequences of 1132 nucleotides
in length, of which 702 were from NSW. Next, the NSW CRF01_AE sequences were split into four
groups according to sampling year, with two new years of sampling added successively: (i) 2004–2009
(n = 149), (ii) 2004–2011 (n = 262), (iii) 2004–2013 (n = 387), (iv) 2004–2015 (n = 542), and (v) 2004–2017
(n = 702), the latter representing the complete data set. A maximum likelihood (ML) tree was estimated,
employing FastTreeMP for each sub-data set, and using the same background data as described
above. An approximate Shimodaira-Hasegawa test was implemented in PhyML v3.1. to test for node
support [17,18]. Phylogenetic trees were visualized in FigTree v1.4.3. The high sampling density in
this study and in potential subsequent studies enables the identification of complete transmission
networks which would compromise patient privacy. Thus, a random subset of 10% of sequence data
(n = 70) from the 702 CRF01_AE samples used in this study are available via NCBI under the accession
numbers MK941065-MK941134 (Table S1).
2.4. Clade Identification
Clade identification was performed using R v3.4.3 [19], and a NSW-specific HIV-1 clade was
defined as a node on the CRF01_AE phylogeny in which at least 80% of all tips were NSW sequences
collected in this study [14,20,21]. ClusterPicker v1.2.5. [22] was used to identify potential active
transmission clusters with that where characterized by a node support of 0.9 or higher and a genetic
distance of 1.5% or lower [23,24].
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3. Results and Discussion
3.1. Increase in non-B HIV-1 Subtype in NSW
Virus subtype was determined and changes in subtype incidence were measured over time for
NSW HIV-1 sequences sampled between 2004–2017 (n = 7000). The proportion of non-B subtype
sequences increased over time: Non-B subtypes comprised an average of 15% of all samples during
2004–2008, an average of 28% of all samples between 2009–2013, and 42% between 2014–2017 (Figure 1).
Notably, CRF01_AE became the most prevalent non-B subtype and second most prevalent subtype
overall in NSW, i.e., approximately 17% of all samples between 2014–2017 were CRF01_AE.Viruses 2019, 11, x FOR PEER REVIEW 4 of 9 
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Figure 1. Changes in HIV-1 subtypes and circulating recombinant form 01_AE (CRF01_AE)_demographics
over time. The proportion of subtypes is mapped across different years. Subtype B = yellow, subtype
CRF01_AE = olive, subtype C = dark cyan, other non-recombinant subtypes = steel, and recombinants = blue.
3.2. Identification of Large NSW-Specific Clades
Virus sequences were available from 2004 onwards. Although sequence numbers were low in
the first three years, they increased steadily between 2007 and 2017, with an average of 62 sequences
available for each year after 2007 (Figure 2). These data were combined with a background data
set consisting f global sequ nces to dentify NSW-specific indepen ent cl des (Figure S1). For the
complete data set including all 702 NSW sequences, a total of 109 NSW-specific clad s were identified,
comprising 463 sequences, representing 66% of all NSW sequences in this study. A total of 50%
(n = 54) of these clades were sequence pairs, with no evidence of additional onwards transmission.
However, 355 sequences fell within 55 clades characterized by three or more sequences, and were
distributed as follows: 19 clades contained three sequences, nine clades contained four sequences,
13 clades containing five sequences, three clades contained six and eight sequences each, two clades
contained nine and ten sequences each, and four clades contained more than 10 sequences, i.e., 14,
16, 19, and 68 sequences, respectiv ly. This clade size patt rn is typical for HIV-1 phylogenies, with
the majori y of clades being small (two sequences), and only a handful of larger clades repres nting
sub-epid mics [25,26]. This pattern also strongly supp rts m ltiple independent virus entrie , i.e.,
individual sub-epidemics, of CRF01_AE in NSW, which arrived in NSW either via acquisition outside
the state due to travel, or migration to NSW.
We next mapped clade duration—that is, the time between the earliest and oldest sequences
present in a clade—onto a time scale (Figure 2). Notably, while some small clades with two to four
sequences were sampled within a short time frame, other small clades contain sequences sampled up
to ten years apart. In fact, of the 100 clades identified, 51 spanned a time frame of three to 12 years, and
44 clades were sampled within one year. Thus, clade number and size appear to be growing over time.
Notably, the background dat set containe uence sampled in Australia; however, only
two of these formed a cluster with the NSW se ces, such that the contributi n of inter-state
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transmission within Australia is seemingly limited, which is in concordance with a previous study
showing that there is only limited clustering between sequences from different states [27].Viruses 2019, 11, x FOR PEER REVIEW 5 of 9 
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Figure 2. Sampling size changes over time. Number of sequences mapped across different years
(bottom). New South Wales (NSW)-specific clade duration is shown by plotting the duration from the
oldest to the most recent sequence sampled within a clade (top). Clades are colored according to clade
size that represents the number of sequences it i each clade.
3.3. Clade Growth is Slow over Time
To asses the rate of clade growth, ences w re split int four different data subsets
according to their year of sampling and co ith the global sequences. The first sub-data set
comprised of 149 NSW sequences sampled between 20 4–20 9. i er ti e r ge as chosen in this
case to enable a solid starting point for clade identification. Two additional sampling years were added
for each subsequent sub-data set. NSW-specific clades were identified for each sub-data set. Clades
where the most recent sequence was sampled before 2016 were classified as temporarily discontinued,
although these may include more recent undiagnosed cases (11% of all HIV-1 infected people living in
Australia are thought to be undiagnosed [9]). Ten such discontinued clades were found (Figure 3A).
Notably, 34 clades were still active in 2017 (ongoing clades) and have been steadily growing over time,
with n addition of one r two sequences for ach two-year period. This includes larger clades found
comprising more than ten sequ nces, and i cluding the large t clade with 68 sequences, all f which
represent independent sub-epidemics. This is consistent with a previous study showing that clades
grow slowly and irregularly [28].
Within the starting data set with sequences up to 2009, approximately 42% of the sequences
represented singletons, and 58% were part of a clade (Figure 3B). Notably, this was the highest ratio of
singleton sequences as the proportion of singleton sequences decreased over time in the following
sub-data sets from 38% in the 2011 sub-data set to 24% in the 2017 data set.
In contrast, the proportion of sequences forming a new cluster increased initially from 15% in the
2011 sub-data set to 17% in the 2013 sub-data se , bu then decreas d again to 14% in the complete
data set (Figure 3B). This could simply be associated with an increase i the extent of sampling (HIV-1
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testing). However, the number of new HIV notifications actually decreased in NSW from 332 in
2011, to 317 in 2016, and 313 notifications in 2017 [6]. Hence, while existing clades are growing
more slowly, new clades are arising, such that public health interventions to stop virus transmission
may be impacting on different populations unevenly. Indeed, epidemiological differences have been
observed between HIV-1 positive individuals born in Australia, and those born overseas; for example
a higher proportion of late diagnoses were observed in overseas born individuals [9]. However, from
the 702 NSW CRF01_AE sequences used in this study, only 51% had available meta data including
transmission risk and country of birth, so that no correlation between demographic factor and clade
size and duration could be performed.
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Figure 3. Discontinued and active ongoing ific clades. (A) Clade size for different clades is
shown across the five sub-dat sets. Discont clades are show in orange with time period for
the most recent sequence sampled shown with a red circle, sustained ongoing clades in blue, all other
clades in black. Clade size for the analyzed time frame is indicated in the legend. (B) The number of
singleton sequences is shown for the five different sub-data sets (dark blue). For each sub-data set new
sequences belonging to an existing clade (blue) from the previous sub-data set, and new sequences
forming a new clade (grey), are also shown. The x-axis defines the sequence sampling date grouped
into the two-year time periods investigated.
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3.4. Potential Active Transmission Networks
Finally, potential direct transmission events were investigated by implementing a distance
threshold of 1.5% and a node support of 99%. Sequences fulfilling these parameters form a transmission
network, representing either direct virus transmission between individuals (i.e., a transmitter-recipient
pair), or virus transmission to two recipients from the same transmitter. Sixteen singleton sequences had
a high similarity to one or more of the global sequences, representing a potential transmitter-recipient
pair between a sequence from overseas and a sequence sampled in NSW, although the directionality
of transmission could not be established. In addition, four NSW-specific clades had a low genetic
distance with one or more sequences from the global data set, indicating that transmission between
sequences from different countries is not uncommon (Figure S2).
Forty NSW-specific sequence pairs had a low genetic distance and high node support, indicative
of a transmission network. Similarly, 13 networks with three sequences, four networks with five
sequences, and one network with four, six, and eight sequences, respectively, were also identified.
One of these has been active for at least six years, which is indicative of active clade growth, and which
could be prevented by focused public health interventions. Notably, in one of the networks all three
sequences share the drug resistance mutations K101E, Y181C and G190S, which can lead to reduced
susceptibility to the non-nucleoside analog reverse transcriptase inhibitor drug class [16].
4. Conclusions
Our study has revealed the depth of active HIV-1 transmission for the CRF01_AE subtype in
NSW, Australia. Importantly, the marked increase in CRF01_AE infections might be associated with an
increase of small local transmission networks forming local sub-epidemics within the state. The slow
growth in clade size and increase in clade number over time identified here highlights the likely
effectiveness of interventions facilitating early diagnosis and contact-tracing.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/5/482/s1,
Figure S1: Global phylogeny of CRF 01_AE; Figure S2: Potential active transmission networks; Table S1:
Accession numbers.
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